The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: An analysis of 25 cases

Journal of Clinical Pathology

Volumn 68, Issue 1, 2015, Pages 44-50

  Sulliva, Harold C ^a   Edgar, Mark A ^a   Cohen, Cynthia ^a   Kovach, Charles K ^a   HooKim, Kim ^b   Reid, Michelle D ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; CYTOKERATIN AE1; CYTOKERATIN AE3; ERG PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; CANCER DIAGNOSIS; CHILD; CLINICAL ARTICLE; CYTODIAGNOSIS; ERYTHROBLAST TRANSFORMATION SPECIFIC RELATED GENE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRESCHOOL CHILD; PROTO ONCOGENE; SARCOMA CELL; SENSITIVITY ANALYSIS; VERY ELDERLY; CHEMISTRY; HEMANGIOSARCOMA; METABOLISM; NEEDLE BIOPSY; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ANTIGENS, CD34; BIOPSY, NEEDLE; CHILD, PRESCHOOL; CYTODIAGNOSIS; FEMALE; HEMANGIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84919363487     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202629     Document Type: Article

References (36)

1. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511
2. Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011;35:1014-20
3. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 2011;459:441-7
4. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010;12:590-8
5. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: Implications for pathological practice. Mod Pathol 2011;24:1128-38
6. Verdu M, Trias I, Roman R, et al. ERG expression and prostatic adenocarcinoma. Virchows Arch 2013;462:639-44
7. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 2011;35:432-41
8. Yaskiv O, Rubin BP, He H, et al. ERG protein expression in human tumors detected with a rabbit monoclonal antibody. Am J Clin Pathol 2012;138:803-10
9. Minner S, Luebke AM, Kluth M, et al. High level of Ets-related gene expression has high specificity for prostate cancer: A tissue microarray study of 11 483 cancers. Histopathology 2012;61:445-53
10. Wang WL, Patel NR, Caragea M, et al. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Mod Pathol 2012;25:1378-83
11. Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 2008;111:3498-506
12. Birdsey GM, Dryden NH, Shah AV, et al. The transcription factor Erg regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood 2012;119:894-903
13. Boucher LD, Swanson PE, Stanley MW, et al. Cytology of angiosarcoma. Findings in fourteen fine-needle aspiration biopsy specimens and one pleural fluid specimen. Am J Clin Pathol 2000;114:210-19
14. Minimo C, Zakowski M, Lin O. Cytologic findings of malignant vascular neoplasms: A study of twenty-four cases. Diagn Cytopathol 2002;26:349-55
15. Liu K, Layfield LJ. Cytomorphologic features of angiosarcoma on fine needle aspiration biopsy. Acta Cytol 1999;43:407-15
16. Ohsawa M, Naka N, Tomita Y, et al. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer 1995;75:2867-74
17. Poblet E, Gonzalez-Palacios F, Jimenez FJ. Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas. Virchows Arch 1996;428:217-21
18. Yang XJ, Zheng JW, Zhou Q, et al. Angiosarcomas of the head and neck: A clinico-immunohistochemical study of 8 consecutive patients. Int J Oral Maxillofac Surg 2010;39:568-72
19. Traweek ST, Kandalaft PL, Mehta P, et al. The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 1991;96:25-31
20. Folpe AL, Veikkola T, Valtola R, et al. Vascular endothelial growth factor receptor-3 (VEGFR-3): A marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 2000;13:180-5
21. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens-evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994;7:82-90
22. Rao P, Lahat G, Arnold C, et al. Angiosarcoma: A tissue microarray study with diagnostic implications. Am J Dermatopathol 2013;35:432-7
23. Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: A study of 80 cases. Am J Surg Pathol 1998;22:683-97
24. Gagner JP, Yim JH, Yang GC. Fine-needle aspiration cytology of epithelioid angiosarcoma: A diagnostic dilemma. Diagn Cytopathol 2005;33:429-33
25. Fletcher CD, Beham A, Bekir S, et al. Epithelioid angiosarcoma of deep soft tissue: A distinctive tumor readily mistaken for an epithelial neoplasm. Am J Surg Pathol 1991;15:915-24
26. Siddaraju N, Soundararaghavan J, Bundele MM, et al. Fine needle aspiration cytology of epithelioid angiosarcoma: A case report. Acta Cytol 2008;52:109-13
27. McKay KM, Doyle LA, Lazar AJ, et al. Expression of ERG, an Ets family transcription factor, distinguishes cutaneous angiosarcoma from histological mimics. Histopathology 2012;61:989-91
28. McKenney JK, Weiss SW, Folpe AL. CD31 expression in intratumoral macrophages: A potential diagnostic pitfall. Am J Surg Pathol 2001;25:1167-73
29. Kuzu I, Bicknell R, Harris AL, et al. Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol 1992;45:143-8
30. Wenig BM, Abbondanzo SL, Heffess CS. Epithelioid angiosarcoma of the adrenal glands. A clinicopathologic study of nine cases with a discussion of the implications of finding "epithelial-specific" markers. Am J Surg Pathol 1994; 18:62-73
31. Gray MH, Rosenberg AE, Dickersin GR, et al. Cytokeratin expression in epithelioid vascular neoplasms. Hum Pathol 1990;21:212-17
32. Liu H, Shi J, Wilkerson M, et al. Immunohistochemical evaluation of ERG expression in various benign and malignant tissues. Ann Clin Lab Sci 2013;43:3-9
33. Miettinen M, Wang Z, Sarlomo-Rikala M, et al. ERG expression in epithelioid sarcoma: A diagnostic pitfall. Am J Surg Pathol 2013;37:1580-5
34. Frank R, Sadri N, Bhatti T, et al. Proximal-type Epithelioid Sarcoma of the Head and Neck (HN): A Study with Immunohistochemical and Molecular Analysis of SMARCB1. J Clin Exp Oncol 2013;2. pii: 1000106
35. Rekhi B, Jambhekar NA. Immunohistochemical validation of INI1/SMARCB1 in a spectrum of musculoskeletal tumors: An experience at a Tertiary Cancer Referral Centre. Pathol Res Pract 2013;209:758-66
36. Stockman DL, Hornick JL, Deavers MT, et al. ERG and FLI1 protein expression in epithelioid sarcoma. Mod Pathol 2013;27:496-501.